ABSTRACT
BACKGROUND: Local treatment with foams in patients suffering from ulcerative proctitis or proctosigmoiditis is considered a rational treatment option. AIMS: To investigate colonic spread, safety, tolerability and acceptance of a newly developed budesonide foam formulation. METHODS: Twelve patients (four females, eight males) with acute proctosigmoiditis or left-sided ulcerative colitis were rectally administered a single dose of [99Tcm]-labelled budesonide foam (Budenofalk; Dr Falk Pharma GmbH, Freiburg, Germany) containing 2 mg budesonide in 20 mL foam after diagnostic colonoscopy. Thereafter, the colonic spread was assessed by means of gamma-scintigraphy for 6 h. Serum samples were taken simultaneously. RESULTS: Budesonide foam spread with a maximum between 11 and 40 cm, thus reaching the sigmoid colon in all patients. In some patients, the foam even extended into the distal third and the middle of the descending colon with maximum radioactivity at 4 h. Systemic budesonide absorption was rapid and pharmacokinetic data were comparable with published data on marketed budesonide enemas, with mean serum C(max) and AUC(0-8 h) values of 0.8 +/- 0.5 ng/mL and 3.7 +/- 1.9 ng h/mL, respectively. The new formulation was well accepted by all patients, who could retain the foam for at least 4 h. CONCLUSIONS: In the majority of patients, budesonide foam effectively spread up to the left-sided colon and thus qualifies for the local treatment of proctosigmoiditis.
Subject(s)
Anti-Inflammatory Agents/pharmacokinetics , Budesonide/pharmacokinetics , Colitis, Ulcerative/drug therapy , Colon/metabolism , Proctocolitis/drug therapy , Administration, Rectal , Anti-Inflammatory Agents/administration & dosage , Budesonide/administration & dosage , Colitis, Ulcerative/diagnostic imaging , Colon/diagnostic imaging , Female , Gamma Cameras , Humans , Male , Prospective Studies , Radionuclide Imaging , TechnetiumABSTRACT
Capecitabine is an oral prodrug of 5-fluorouracil (FU). Since FU concentrations achieved in malignant lesions are an important determinant of efficacy, we investigated the intratumoral transcapillary transfer of capecitabine and its metabolites in vivo. A total of 10 patients with skin metastases from breast cancer received a daily dose of 2500 mg m(-2) capecitabine administered orally in two divided doses for 2 weeks. Microdialysis probes were inserted into a cutaneous metastasis and subcutaneous connective tissue to evaluate the interstitial tissue pharmacokinetics of capecitabine and its metabolites 5'-deoxy-5-fluorocytidine (DFCR), 5'-deoxy-5-fluorouridine (DFUR), and FU by capillary electrophoresis. As intended with the prodrug design of capecitabine, FU was present in low concentrations in tumour interstitium (median c(max): 0.26 microg ml(-1)) when compared with capecitabine, DFCR, and DFUR (median c(max): 2.66, 4.22, and 2.13 microg ml(-1), respectively). Capecitabine and its metabolites easily penetrated malignant and healthy tissue and equilibrated within 45 min between plasma and tissue interstitium. Considering tissue exposure at the extracellular level, no significant differences between healthy and malignant tissues were observed. Our data show that absorption and metabolism determined the tissue pharmacokinetics of capecitabine. There was no evidence of drug tolerance, which may be attributed to impaired transcapillary transfer into tissue, even after repeated administration as shown for three patients.
Subject(s)
Antimetabolites, Antineoplastic/pharmacokinetics , Breast Neoplasms/metabolism , Deoxycytidine/analogs & derivatives , Deoxycytidine/pharmacokinetics , Adult , Aged , Aged, 80 and over , Antimetabolites, Antineoplastic/therapeutic use , Area Under Curve , Breast Neoplasms/drug therapy , Capecitabine , Deoxycytidine/therapeutic use , Electrophoresis, Capillary , Fluorouracil/analogs & derivatives , Humans , Microdialysis , Middle AgedSubject(s)
Antimetabolites, Antineoplastic/pharmacokinetics , Breast Neoplasms/metabolism , Deoxycytidine/analogs & derivatives , Deoxycytidine/pharmacokinetics , Prodrugs/pharmacokinetics , Skin Neoplasms/metabolism , Administration, Oral , Antimetabolites, Antineoplastic/metabolism , Antimetabolites, Antineoplastic/therapeutic use , Breast Neoplasms/drug therapy , Breast Neoplasms/pathology , Capecitabine , Deoxycytidine/metabolism , Deoxycytidine/therapeutic use , Electrophoresis, Capillary , Extracellular Space/metabolism , Floxuridine/metabolism , Fluorouracil/analogs & derivatives , Humans , Prodrugs/metabolism , Prodrugs/therapeutic use , Skin Neoplasms/drug therapy , Skin Neoplasms/secondary , Tissue DistributionABSTRACT
BACKGROUND: Dacarbazine has been on the market for approximately 3 decades but remains the most effective single agent available for the therapy of metastatic malignant melanoma (MMM). Most MMMs, however, respond poorly to dacarbazine therapy. Apart from tumor resistance at a molecular level, several studies support the notion that therapeutic failure in tumor therapy also might be attributed to an impaired transcapillary drug transfer. METHODS: On the basis of this hypothesis, the authors measured intratumor transcapillary transfer rates of dacarbazine and its active metabolite 5-aminoimidazole-4-carboxamide (AIC) by in vivo microdialysis after intravenous administration of dacarbazine at doses of 200 mg/m(2) to 1000 mg/m(2) (n = 7) in patients suffering from MMM. RESULTS: For all doses, area under the concentration curve (AUC) values for dacarbazine and AIC were not significantly different between plasma and tumor interstitium with AUC(tumor)/AUC(plasma) ratios of 0.97 +/- 0.08 (mean +/- standard error of the mean) for dacarbazine and 0.76 +/- 0.22 for AIC. AUC(0-240) values for dacarbazine and AIC measured in plasma correlated closely with corresponding AUC(0-240)values measured in the interstitium of MMMs with values of r(s) = 0.82 (P = 0.042) and r(s) = 0.90 (P = 0.037), respectively. CONCLUSIONS: The results of this study indicate favorable tumor penetration characteristics of dacarbazine and its active metabolite AIC. The relative lack of response to antineoplastic therapy with dacarbazine, thus might be explained by resistance of melanoma cells at a molecular level rather than by an inability of dacarbazine and AIC to penetrate into the interstitium of MMM.
Subject(s)
Antineoplastic Agents, Alkylating/pharmacokinetics , Dacarbazine/pharmacokinetics , Melanoma/drug therapy , Skin Neoplasms/drug therapy , Aged , Aminoimidazole Carboxamide/metabolism , Antineoplastic Agents, Alkylating/metabolism , Antineoplastic Agents, Alkylating/therapeutic use , Area Under Curve , Chromatography, High Pressure Liquid , Dacarbazine/metabolism , Dacarbazine/therapeutic use , Extracellular Space/metabolism , Female , Humans , Male , Melanoma/metabolism , Melanoma/secondary , Microdialysis , Middle Aged , Skin Neoplasms/metabolism , Skin Neoplasms/pathologyABSTRACT
Although the transdermal administration of drugs has gained considerable importance, reliable methods for the quantitative assessment of transdermal drug penetration are scarce. The aim of the present study was therefore to evaluate the scopes and limits of the minimal trauma tissue biopsy (MTTB) technique for the in vivo characterization of the transdermal penetration process and the assessment of dermal drug kinetics in humans following topical drug application. Nicotine TTS (21 mg/24 h) was administered transdermally to 13 healthy volunteers. Repeated minimally invasive dermal and subdermal tissue biopsies were obtained at defined time points from defined skin layers directly underlying the TTS. The position of the biopsy needle and depth of biopsate were determined by 2D ultrasound scanning. The biopsy procedure was well tolerated by all volunteers and up to six biopsies within a period of 10 h were easily accepted. Dermal pharmacokinetic profiles for nicotine were obtained in all experiments and corresponded well to the values measured in previous studies on transdermal nicotine penetration. Mean area under the nicotine concentration time curve (AUC) in subepidermal layers underneath the application site of the TTS was 70.0+/-55.1 microg/g per h. There was a correlation between the depth of biopsy sampling and dermal nicotine concentrations at steady state (r=0.7). The MTTB is a suitable, well tolerated technique for the detection of transdermally applied compounds in defined subepidermal tissue layers and could therefore become a valuable tool in the development and assessment of transdermal dosage forms.
Subject(s)
Pharmacokinetics , Skin/metabolism , Administration, Cutaneous , Adult , Biopsy , Humans , Nicotine/pharmacokineticsABSTRACT
OBJECTIVE: Emedastine difumarate is a new H1 receptor antagonist with well defined pharmacokinetic and pharmacodynamic profiles in healthy volunteers. However, to date it is not known whether impaired renal function in patients with chronic renal insufficiency affects its pharmacokinetics and probably also its tolerability. Therefore, we here set out to compare the pharmacokinetics of emedastine difumarate in patients suffering from different degrees of renal failure with a control group of healthy volunteers. METHODS AND RESULTS: For this purpose we conducted an open, single-centre, comparative parallel group study in patients and healthy volunteers. Emedastine difumarate 2 mg was administered orally to the study population in single and seven repetitive doses twice daily (b.i.d.). Pharmacokinetics differed markedly between volunteers (n = 6) and patients (n = 17). The maximum serum concentration of emedastine (Cmax), area under the serum concentration-time curve, mean residence time and terminal disposition half-life were significantly higher in patients (P < 0.05), while time to reach Cmax and apparent volume of disposition were not statistically different after single and repeated (steady-state) oral administrations. Blood pressure and heart rate were also not affected by the study medication. CONCLUSION: The present study shows that impaired renal function alters the pharmacokinetics of emedastine in plasma. Thus, dose adjustment of emedastine difumarate is advisable in patients with impaired renal function.
Subject(s)
Benzimidazoles/pharmacokinetics , Histamine H1 Antagonists/pharmacokinetics , Renal Insufficiency/metabolism , Administration, Oral , Adult , Area Under Curve , Female , Half-Life , Humans , Linear Models , Male , Metabolic Clearance Rate , Middle AgedABSTRACT
BACKGROUND: Previous studies have suggested that statins exert beneficial effects beyond their favorable lipid lowering effect. Particularly, the modification of thrombus formation and degradation, alteration in inflammatory response, plaque stabilization and improved endothelial function are thought to be responsible for additional reduction of morbidity and mortality due to cardiovascular events. To date, however, it is still unclear whether these effects are elicited by all statins. METHODS AND RESULTS: We set out to compare in a controlled, randomized, double-blind study design the effects of almost equieffective cholesterol lowering doses of three chemically and pharmacokinetically different statins (atorvastatin, simvastatin, pravastatin) on hemostatic and inflammatory markers in 99 hypercholesterolemic patients. At entry and 3 months after onset of statin therapy plasma cholesterol and von Willebrand factor antigen (vWf-Ag), fibrinogen, d-dimer, prothrombin fragment 1+2 (F1.2) and C-reactive protein (CRP) were measured. The effect on plasma values of F1.2, vWf-Ag, d-dimer and CRP was not significantly different between the three treatment groups. The effect of simvastatin on fibrinogen (p = 0.005) was more pronounced than the effects of atorvastatin (p = 0.48 n.s.) and pravastatin (p = 0.15 n.s.). Plasma levels of F1.2 and vWf-Ag (when data of all statins were pooled) were significantly reduced by 7% and 10% versus baseline, respectively. No significant reduction was observed for d-dimer (p = 0.26) and CRP (p = 0.5). Total plasma cholesterol levels decreased significantly (p < 0.0001 in all groups) between 22% and 29% compared to baseline. CONCLUSION: The present study shows similar short-term (3 months) effects of atorvastatin, simvastatin and pravastatin on selected hemostatic and inflammatory parameters in plasma in patients with hypercholesterolemia. Thus, chemical and pharmacological differences between statins appear to exert no major influence on these parameters.